364 related articles for article (PubMed ID: 23664695)
1. Mechanism and novel therapeutic approaches to wasting in chronic disease.
Ebner N; Springer J; Kalantar-Zadeh K; Lainscak M; Doehner W; Anker SD; von Haehling S
Maturitas; 2013 Jul; 75(3):199-206. PubMed ID: 23664695
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to the treatment of cachexia.
Argilés JM; López-Soriano FJ; Busquets S
Drug Discov Today; 2008 Jan; 13(1-2):73-8. PubMed ID: 18190867
[TBL] [Abstract][Full Text] [Related]
3. The cancer anorexia-cachexia syndrome.
Nelson KA
Semin Oncol; 2000 Feb; 27(1):64-8. PubMed ID: 10697022
[TBL] [Abstract][Full Text] [Related]
4. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting.
Gullett NP; Hebbar G; Ziegler TR
Am J Clin Nutr; 2010 Apr; 91(4):1143S-1147S. PubMed ID: 20164318
[TBL] [Abstract][Full Text] [Related]
5. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.
Koopman R; Ryall JG; Church JE; Lynch GS
Curr Opin Clin Nutr Metab Care; 2009 Nov; 12(6):601-6. PubMed ID: 19741516
[TBL] [Abstract][Full Text] [Related]
6. The pathophysiology of cachexia in chronic obstructive pulmonary disease.
Schols AM; Gosker HR
Curr Opin Support Palliat Care; 2009 Dec; 3(4):282-7. PubMed ID: 19713853
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin: from discovery to cancer cachexia therapy.
Molfino A; Formiconi A; Rossi Fanelli F; Muscaritoli M
Curr Opin Clin Nutr Metab Care; 2014 Sep; 17(5):471-6. PubMed ID: 24905862
[TBL] [Abstract][Full Text] [Related]
8. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach.
Pasini E; Aquilani R; Gheorghiade M; Dioguardi FS
Ital Heart J; 2003 Apr; 4(4):232-5. PubMed ID: 12784775
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological treatment of cachexia.
Argilés JM; Almendro V; Busquets S; López-Soriano FJ
Curr Drug Targets; 2004 Apr; 5(3):265-77. PubMed ID: 15058312
[TBL] [Abstract][Full Text] [Related]
10. Using megestrol acetate to ameliorate protein-energy wasting in chronic kidney disease.
Smith CS; Logomarsino JV
J Ren Care; 2016 Mar; 42(1):53-9. PubMed ID: 26537025
[TBL] [Abstract][Full Text] [Related]
11. Acylated and unacylated ghrelin administration to blunt muscle wasting.
Reano S; Graziani A; Filigheddu N
Curr Opin Clin Nutr Metab Care; 2014 May; 17(3):236-40. PubMed ID: 24572833
[TBL] [Abstract][Full Text] [Related]
12. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
13. The role of ghrelin and ghrelin analogues in wasting disease.
Kamiji MM; Inui A
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):443-51. PubMed ID: 18542005
[TBL] [Abstract][Full Text] [Related]
14. Involuntary weight loss: the forgotten vital sign.
J Support Oncol; 2003; 1(2):142. PubMed ID: 15352658
[No Abstract] [Full Text] [Related]
15. Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect.
Akamizu T; Kangawa K
Peptides; 2011 Nov; 32(11):2295-300. PubMed ID: 21635929
[TBL] [Abstract][Full Text] [Related]
16. Latest consensus and update on protein-energy wasting in chronic kidney disease.
Obi Y; Qader H; Kovesdy CP; Kalantar-Zadeh K
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):254-62. PubMed ID: 25807354
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial plasticity in cancer-related muscle wasting: potential approaches for its management.
Vitorino R; Moreira-Gonçalves D; Ferreira R
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):226-33. PubMed ID: 25783794
[TBL] [Abstract][Full Text] [Related]
18. Definition and classification of cancer cachexia: an international consensus.
Fearon K; Strasser F; Anker SD; Bosaeus I; Bruera E; Fainsinger RL; Jatoi A; Loprinzi C; MacDonald N; Mantovani G; Davis M; Muscaritoli M; Ottery F; Radbruch L; Ravasco P; Walsh D; Wilcock A; Kaasa S; Baracos VE
Lancet Oncol; 2011 May; 12(5):489-95. PubMed ID: 21296615
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cachexia with ghrelin in patients with COPD.
Nagaya N; Itoh T; Murakami S; Oya H; Uematsu M; Miyatake K; Kangawa K
Chest; 2005 Sep; 128(3):1187-93. PubMed ID: 16162705
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms and treatment options for muscle wasting diseases.
Rüegg MA; Glass DJ
Annu Rev Pharmacol Toxicol; 2011; 51():373-95. PubMed ID: 20936944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
